| Schedule of Segment Information |
Selected financial information for the Company’s
operating segments was as follows:
| |
|
Three Months Ended March 31, |
|
| |
|
2020 |
|
|
2019 |
|
| Net revenues – External |
|
|
|
|
|
|
|
|
| Hospital Operations |
|
$ |
1,840,091 |
|
|
$ |
5,105,265 |
|
| Clinical Laboratory Operations |
|
|
1,440 |
|
|
|
85,385 |
|
| |
|
$ |
1,841,531 |
|
|
$ |
5,190,650 |
|
| Net loss from continuing operations before income taxes |
|
|
|
|
|
|
|
|
| Hospital Operations |
|
$ |
(3,092,933 |
) |
|
$ |
(3,175,107 |
) |
| Clinical Laboratory Operations |
|
|
(113,386 |
) |
|
|
(225,530 |
) |
| Corporate |
|
|
(645,866 |
) |
|
|
(1,072,835 |
) |
| Other expense, net |
|
|
(3,018,303 |
) |
|
|
(8,459,323 |
) |
| |
|
$ |
(6,870,488 |
) |
|
$ |
(12,932,795 |
) |
| Depreciation and amortization |
|
|
|
|
|
|
|
|
| Hospital Operations |
|
$ |
182,315 |
|
|
$ |
173,776 |
|
| Clinical Laboratory Operations |
|
|
(17,743 |
) |
|
|
49,662 |
|
| Corporate |
|
|
135 |
|
|
|
148 |
|
| |
|
$ |
164,707 |
|
|
$ |
223,586 |
|
| Capital expenditures |
|
|
|
|
|
|
|
|
| Hospital Operations |
|
$ |
- |
|
|
$ |
42,317 |
|
| |
|
$ |
- |
|
|
$ |
42,317 |
|
| |
|
As of |
|
| |
|
March 31, 2020 |
|
|
December 31, 2019 |
|
| Total assets |
|
|
|
|
|
|
|
|
| Hospital Operations |
|
$ |
13,186,606 |
|
|
$ |
14,275,256 |
|
| Clinical Laboratory Operations |
|
|
278,011 |
|
|
|
330,381 |
|
| Corporate |
|
|
4,531,979 |
|
|
|
2,305,380 |
|
| Assets of AMSG and HTS classified as held for sale |
|
|
487,278 |
|
|
|
514,772 |
|
| Eliminations |
|
|
(2,718,130 |
) |
|
|
(2,718,130 |
) |
| |
|
$ |
15,765,744 |
|
|
$ |
14,707,659 |
|
|